CereCura Nanotherapeutics Inc.

Based in Canada, CereCura Nanotherapeutics Inc. specializes in developing RNA therapeutics leveraging lipid nanoparticle technology to address neurological disorders and brain diseases. Based in Vancouver, Canada and founded in 2022 by co-founders Louis-Phillippe Bernier, Nicholas Weilinger, Richard Howlet, Brian MacVicar and Pieter Cullis, CereCura Nanotherapeutics Inc. , focuses on leveraging lipid nanoparticle (LNP) technology to deliver RNA-based treatments safely and precisely to the brain.

In September 2025, CereCura Nanotherapeutics Inc. raised CAD 1. 4 million in seed funding led by investor WUTIF Capital (VCC), with participation from other investors eFund, UBC Venture Funds, and HexTwo Capital. CereCura Nanotherapeutics specializes in developing innovative RNA therapeutics specifically designed to address brain diseases through the application of lipid nanoparticle (LNP) technology.

Their core product offerings are centered around LNP-RNA therapeutics, which enable the precise and safe delivery of RNA molecules for therapeutic purposes. These therapies aim to empower the brain to synthesize its own biologics, targeting the complex mechanisms underlying various neurological disorders. The company's solutions are geared toward transforming the treatment landscape for conditions that affect a significant portion of the population, with a focus on providing effective interventions for patients suffering from brain diseases. CereCura serves a diverse clientele, including academic institutions, biotechnology firms, and pharmaceutical organizations, primarily in North America and Europe, with ongoing collaborations designed to enhance the reach and efficacy of their products.

CereCura Nanotherapeutics generates revenue through strategic partnerships and collaborative agreements with various stakeholders in the pharmaceutical and biotechnology sectors. These transactions typically involve collaborative research and development agreements, where partners contribute to the development and commercialization of LNP-RNA therapeutics. The company may structure its revenue model around milestone payments and royalties derived from successful product development and commercialization efforts. While specific pricing plans for their therapeutics are not disclosed, the business model emphasizes the value of collaboration, with potential revenue streams linked to the advancement and regulatory approval of their RNA-based offerings.

Their focus on partnerships highlights the firm’s commitment to innovation and expansion within the neurology therapeutic landscape. CereCura Nanotherapeutics plans to leverage its recent funding to support the development of new RNA therapeutics targeting neurological disorders. The company is exploring expanding its market presence in Europe and North America by the end of 2024. Additionally, the recent investment from new partner Hex Two Capital will facilitate the enhancement of their research and development capabilities, further enabling them to innovate within the neurology sector.